BioNTech (NASDAQ:BNTX) Upgraded at The Goldman Sachs Group

BioNTech (NASDAQ:BNTX) was upgraded by The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued on Friday,Finviz reports. The brokerage presently has a $137.00 price objective on the stock, up from their prior price objective of $90.00. The Goldman Sachs Group’s target price indicates a potential upside of 26.99% from the stock’s previous close.

A number of other analysts have also recently commented on the stock. JPMorgan Chase & Co. cut their target price on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating for the company in a research note on Monday. Jefferies Financial Group raised shares of BioNTech from a “hold” rating to a “buy” rating and raised their price target for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Morgan Stanley raised shares of BioNTech from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Bank of America raised their target price on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, UBS Group boosted their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a report on Wednesday, September 18th. Four research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, BioNTech presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Price Performance

NASDAQ:BNTX opened at $107.88 on Friday. The firm has a market cap of $25.65 billion, a price-to-earnings ratio of -51.37 and a beta of 0.26. BioNTech has a one year low of $76.53 and a one year high of $131.49. The firm’s fifty day moving average is $111.40 and its two-hundred day moving average is $96.39. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.34%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the business earned $0.73 earnings per share. The firm’s revenue was up 38.9% on a year-over-year basis. Research analysts expect that BioNTech will post -2.93 EPS for the current year.

Hedge Funds Weigh In On BioNTech

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC acquired a new position in BioNTech during the 1st quarter worth $314,000. SG Americas Securities LLC lifted its stake in BioNTech by 610.5% during the first quarter. SG Americas Securities LLC now owns 70,143 shares of the company’s stock worth $6,471,000 after purchasing an additional 60,270 shares during the last quarter. QRG Capital Management Inc. increased its stake in BioNTech by 32.9% in the first quarter. QRG Capital Management Inc. now owns 16,731 shares of the company’s stock valued at $1,543,000 after purchasing an additional 4,144 shares during the last quarter. ProShare Advisors LLC raised its stake in BioNTech by 10.4% during the 1st quarter. ProShare Advisors LLC now owns 6,785 shares of the company’s stock valued at $626,000 after acquiring an additional 637 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its position in BioNTech by 2.3% during the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 9,800 shares of the company’s stock worth $904,000 after acquiring an additional 223 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.